Literature DB >> 21600819

Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources.

Atika Benbernou1, Mélanie Drolet, Myron J Levin, Kenneth E Schmader, Michael N Oxman, Robert Johnson, David Patrick, Stéphanie Camden, James A Mansi, Marc Brisson.   

Abstract

BACKGROUND: Herpes zoster results from the reactivation of the varicella-zoster virus, which is often accompanied by a prodrome of dermatomal pain. Little is known about the burden of prodromal pain.
OBJECTIVES: (1) Describe the frequency, severity and duration of prodromal pain; (2) determine the relationship between prodromal pain and the characteristics of herpes zoster at recruitment and the utilization of health care resources.
METHODS: Between 10/2005 and 07/2006, 251 subjects ≥ 50 years old, seeking care for herpes zoster within 14 days of rash onset, were recruited across Canada. Severity and duration of prodromal pain were measured retrospectively using the Initial Zoster Impact Questionnaire. The burden of prodromal pain was obtained by the product of pain severity and duration. The severity of acute herpes zoster pain was measured using the Zoster Brief Pain Inventory.
RESULTS: The majority of participants reported prodromal pain (74%). Mean pain duration and severity were 4.7 days and 6/10, respectively. Subjects aged 61-70 years old were more likely to report prodromal pain (RR=1.14, p-value=0.02). The burden of prodromal pain was greater in subjects not working (p-value=0.02) or immunosuppressed (p-value=0.04). Prodromal pain was associated with more severe acute pain (6.2 vs. 4.3, p-value 0.0001). Compared to subjects who did not report prodromal pain, those with this pain were more likely to receive antivirals (RR=1.18, p-value=0.04) and to visit the emergency room (RR=2.56, p-value=0.04).
CONCLUSION: The burden of prodromal pain is significant and should be considered when evaluating the overall benefit of herpes zoster vaccination. Copyright Â
© 2011 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21600819     DOI: 10.1016/j.ejpain.2011.04.014

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  4 in total

1.  Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States.

Authors:  Parinaz Ghaswalla; Philippe Thompson-Leduc; Wendy Y Cheng; Colin Kunzweiler; Min-Jung Wang; Michael Bogart; Brandon J Patterson; Mei Sheng Duh; John Wojciehowski; Suna Park; Barbara P Yawn
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

2.  Acute Pain Medicine in the United States: A Status Report.

Authors:  Patrick Tighe; Chester C Buckenmaier; Andre P Boezaart; Daniel B Carr; Laura L Clark; Andrew A Herring; Michael Kent; Sean Mackey; Edward R Mariano; Rosemary C Polomano; Gary M Reisfield
Journal:  Pain Med       Date:  2015-06-10       Impact factor: 3.750

Review 3.  A systematic review of the cost effectiveness of herpes zoster vaccination.

Authors:  Thomas D Szucs; Alena M Pfeil
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.558

Review 4.  Vaccination against herpes zoster in developed countries: state of the evidence.

Authors:  Mélanie Drolet; Michael N Oxman; Myron J Levin; Kenneth E Schmader; Robert W Johnson; David Patrick; James A Mansi; Marc Brisson
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.